EBV-specific T cells to prevent EBV after stem cell transplant
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial tests giving special immune cells (EBV-specific T cells) from the donor to prevent Epstein-Barr virus (EBV) infections after a stem cell transplant. It may help people who have a high risk of EBV reactivation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had or will have a stem cell transplant from a donor.
- You or your donor had EBV in your blood before transplant, or you had EBV after transplant without it reaching your plasma.
- You have a condition linked to EBV (like lymphoma or chronic active EBV) that led to the transplant, or you had EBV in the past and need a transplant for another disease.
- Your kidney, liver, and general health are good enough (e.g., no severe kidney or liver problems, no serious infections, and you are expected to live more than 6 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
This trial tests an mRNA vaccine that may help prevent Epstein-Barr virus (EBV) infections and related diseases after a stem cell transplant. It is for people who have received or will receive a donor stem cell transplant.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Hear when a new Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.